CO5050367A1 - Nueva composicion - Google Patents
Nueva composicionInfo
- Publication number
- CO5050367A1 CO5050367A1 CO99025940A CO99025940A CO5050367A1 CO 5050367 A1 CO5050367 A1 CO 5050367A1 CO 99025940 A CO99025940 A CO 99025940A CO 99025940 A CO99025940 A CO 99025940A CO 5050367 A1 CO5050367 A1 CO 5050367A1
- Authority
- CO
- Colombia
- Prior art keywords
- vaccine composition
- composition according
- per
- new composition
- hav
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 abstract 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 abstract 6
- 241000709721 Hepatovirus A Species 0.000 abstract 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 abstract 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Una composición de vacuna acuosa que comprende 0,015-0,1 mgde fosfato de aluminio por µg de antígeno de superficie de la hepatitis B.Una composición de vacuna según la reivindicación 1, que comprende además un virus de la hepatitis A (HAV) inactivado.Una composición de vacuna según la reivindicación 2, que comprende además hidróxido de aluminio. Una composición de vacuna según la reivindicación 3, que comprende 0,05-0,10 mg de hidróxido de aluminio por ml.Una composición de vacuna según cualquiera de las reivindicaciones anteriores, que comprende además formaldehído.Una composición de vacuna según la reivindicación 5, en la que la concentración de formaldehído varía de aproximadamente 10-200 µg por ml.Una vacuna según cualquiera de las reivindicaciones 2 a 6, en la que la concentración de HAV varía de aproximadamente 720-2880 EU por ml.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9809507.8A GB9809507D0 (en) | 1998-05-01 | 1998-05-01 | Novel composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5050367A1 true CO5050367A1 (es) | 2001-06-27 |
Family
ID=10831426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO99025940A CO5050367A1 (es) | 1998-05-01 | 1999-04-29 | Nueva composicion |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP1073462B1 (es) |
| JP (2) | JP5138843B2 (es) |
| KR (1) | KR100612547B1 (es) |
| CN (1) | CN1263509C (es) |
| AR (1) | AR016987A1 (es) |
| AT (1) | ATE345815T1 (es) |
| AU (1) | AU743759B2 (es) |
| BR (1) | BR9910157A (es) |
| CA (1) | CA2331086C (es) |
| CO (1) | CO5050367A1 (es) |
| CY (1) | CY1107322T1 (es) |
| CZ (1) | CZ301232B6 (es) |
| DE (1) | DE69934108T2 (es) |
| DK (1) | DK1073462T3 (es) |
| ES (1) | ES2277437T3 (es) |
| GB (1) | GB9809507D0 (es) |
| GC (1) | GC0000101A (es) |
| HK (1) | HK1034202A1 (es) |
| HU (1) | HU228209B1 (es) |
| IL (1) | IL139269A0 (es) |
| MY (1) | MY128929A (es) |
| NO (1) | NO20005483L (es) |
| NZ (1) | NZ507902A (es) |
| PL (1) | PL190729B1 (es) |
| PT (1) | PT1073462E (es) |
| TR (1) | TR200003235T2 (es) |
| TW (1) | TW553744B (es) |
| WO (1) | WO1999056772A2 (es) |
| ZA (1) | ZA200006118B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1513555A (zh) * | 2003-07-31 | 2004-07-21 | 长春生物制品研究所 | 甲-乙型肝炎联合疫苗及其冻干制剂 |
| EP1862176A1 (de) * | 2006-05-31 | 2007-12-05 | Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH | Ein Verfahren zur Herstellung einer Impfzusammensetzung |
| EP1862177A1 (de) * | 2006-06-01 | 2007-12-05 | Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH | Ein Verfahren zur Herstellung einer Impfzusammensetzung |
| CN102198270B (zh) * | 2011-05-16 | 2012-06-27 | 大连汉信生物制药有限公司 | 一种含铝佐剂乙肝疫苗的制备方法 |
| KR101281098B1 (ko) * | 2011-06-30 | 2013-07-02 | 주식회사 녹십자 | Ｂ형 간염 바이러스 표면 항원상의 에피토프 및 이의 용도 |
| CN102988975A (zh) * | 2012-11-30 | 2013-03-27 | 深圳康泰生物制品股份有限公司 | 甲型、乙型肝炎联合疫苗及其制备方法 |
| US9849066B2 (en) | 2013-04-24 | 2017-12-26 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0349686A (ja) * | 1989-07-11 | 1991-03-04 | Smithkline Biologicals Sa | レトロウイルスｇａｇ蛋白の真核生物細胞における発現 |
| ATE168271T1 (de) * | 1992-05-23 | 1998-08-15 | Smithkline Beecham Biolog | Kombinierte impfstoffe, die hepatitis b oberfläche antigen und andere antigenen enthalten |
| GB9503863D0 (en) * | 1995-02-25 | 1995-04-19 | Smithkline Beecham Biolog | Vaccine compositions |
| EP0845270B1 (en) * | 1996-03-23 | 2004-10-27 | The Research Foundation For Microbial Diseases Of Osaka University | Functional fragment antigen of tetanus toxin and tetanus vaccine |
-
1998
- 1998-05-01 GB GBGB9809507.8A patent/GB9809507D0/en not_active Ceased
-
1999
- 1999-04-27 CZ CZ20004061A patent/CZ301232B6/cs not_active IP Right Cessation
- 1999-04-27 EP EP99924871A patent/EP1073462B1/en not_active Expired - Lifetime
- 1999-04-27 KR KR1020007012162A patent/KR100612547B1/ko not_active IP Right Cessation
- 1999-04-27 GC GCP1999139 patent/GC0000101A/xx active
- 1999-04-27 AU AU41379/99A patent/AU743759B2/en not_active Expired
- 1999-04-27 IL IL13926999A patent/IL139269A0/xx not_active IP Right Cessation
- 1999-04-27 PL PL99344137A patent/PL190729B1/pl unknown
- 1999-04-27 DK DK99924871T patent/DK1073462T3/da active
- 1999-04-27 NZ NZ507902A patent/NZ507902A/en unknown
- 1999-04-27 TR TR2000/03235T patent/TR200003235T2/xx unknown
- 1999-04-27 BR BR9910157-2A patent/BR9910157A/pt not_active Application Discontinuation
- 1999-04-27 AT AT99924871T patent/ATE345815T1/de active
- 1999-04-27 CA CA2331086A patent/CA2331086C/en not_active Expired - Lifetime
- 1999-04-27 HU HU0101652A patent/HU228209B1/hu unknown
- 1999-04-27 WO PCT/EP1999/003024 patent/WO1999056772A2/en active IP Right Grant
- 1999-04-27 PT PT99924871T patent/PT1073462E/pt unknown
- 1999-04-27 CN CNB998081418A patent/CN1263509C/zh not_active Expired - Lifetime
- 1999-04-27 ES ES99924871T patent/ES2277437T3/es not_active Expired - Lifetime
- 1999-04-27 JP JP2000546796A patent/JP5138843B2/ja not_active Expired - Lifetime
- 1999-04-27 DE DE69934108T patent/DE69934108T2/de not_active Expired - Lifetime
- 1999-04-29 MY MYPI99001705A patent/MY128929A/en unknown
- 1999-04-29 CO CO99025940A patent/CO5050367A1/es unknown
- 1999-04-29 AR ARP990102002A patent/AR016987A1/es unknown
- 1999-06-29 TW TW088110991A patent/TW553744B/zh not_active IP Right Cessation
-
2000
- 2000-10-30 ZA ZA200006118A patent/ZA200006118B/xx unknown
- 2000-10-31 NO NO20005483A patent/NO20005483L/no not_active Application Discontinuation
-
2001
- 2001-07-13 HK HK01104910A patent/HK1034202A1/xx not_active IP Right Cessation
-
2007
- 2007-02-08 CY CY20071100163T patent/CY1107322T1/el unknown
-
2010
- 2010-06-29 JP JP2010148061A patent/JP2010209118A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATA155598A (de) | Neue influenzavirus-impfstoffzusammensetzung | |
| CO5210894A1 (es) | Composiciones adyudantes que comprenden una sal de aluminio y un inmunoestimulante | |
| CY1106310T1 (el) | Καθορισμος hbv αντιγονων για χρηση σε εμβολια | |
| CY1107457T1 (el) | Εμβoλιο κατa του hpv | |
| DK0528859T3 (da) | Oral vaccine, som omfatter antigen knyttet til overfladen af røde blodlegemer | |
| BRPI9911870B8 (pt) | vacina de parvovírus e circovírus de suíno | |
| CO4960659A1 (es) | Vacuna que comprende un antigeno de virus de la hepatitis b y un antigeno del virus herpes simplex | |
| BR9809425A (pt) | Conjugados alfa interferon-polietilenoglicol para terapia de infecção | |
| EA200300023A1 (ru) | 3'-ПРОЛЕКАРСТВА 2'-ДЕЗОКСИ-β-L-НУКЛЕОЗИДОВ | |
| DE60210456D1 (de) | Solubisierung von kapseln polysacchariden | |
| ATE320493T1 (de) | Modifizierung des hepatitis b kernantigens | |
| UY26724A1 (es) | Métodos y composiciones para tratar el virus de la hepatitis c | |
| DE60226911D1 (de) | Entwicklung einer Vakzine zur Prävention von Infektionen mit Filovirus bei Primaten | |
| EA199700126A1 (ru) | Вакцина против гепатита в | |
| NO982497D0 (no) | Vaksine-sammensetninger for inntak gjennom nesen | |
| UA85536C2 (en) | Viral antigens | |
| CO5050367A1 (es) | Nueva composicion | |
| ES2140652T3 (es) | Uso de n-alquil-derivados de 1,5-didesoxi-1,5-imino-d-glucitol para el tratamiento de infecciones por el virus de la hepatitis b. | |
| DE60123042D1 (de) | L-fmau zur behandlung von hepatitis-delta-virus-infizierung | |
| ES2195370T3 (es) | Procedimiento para la preparacion de 2`-fluoro-5-metil-beta-l-arabinofuranosiluridina. | |
| MY126520A (en) | A reinforced immunogen for an inactivated vaccine against infectious disease caused by the group of japanese encephalitis virus and a method for producing the same | |
| MX9304349A (es) | Vacuna antirrabica no virulenta. | |
| EP1543165A4 (en) | ASSEMBLY ASSAYS FOR NUCLEOCAPSIDE EBOLA VIRUS | |
| ATE489966T1 (de) | Verbundsuperimmunogen zur verwendung als bifunktioneller impfstoff (tat-gp160) zur behandlung von aids | |
| ATE431745T1 (de) | Ltb4 als adjuvans für impfstoffe |